Anke Biotech updates governance, repurchases shares, elects new board

Anhui Anke Biotechnology Group's board of directors approved changes to its corporate charter and governance documents in November 2025, streamlining operational procedures and enhancing investor protection. The updates involve a reduction in registered capital from RMB 1,672,553,658 to RMB 1,671,320,708 due to the repurchase and cancellation of 924,050 restricted shares, affecting both unvested and ineligible stock options. This share repurchase cost the company RMB 4,855,759.50 of its own funds.

These changes encompass revised policies for external investments, financial assistance, information disclosure, and internal audit mechanisms to align with new legal and regulatory requirements. The company also announced the nomination of new board members for the ninth session, comprising seven non-independent and four independent directors, to be approved by shareholders.

The company's updated governance aims to enhance risk management and operational efficiency, promoting sustainable growth while adhering to principles of fairness and transparency. The investor relations, internal audit, and executive work guidelines have been refined to support these strategic goals.